Page 3 - Peter Guenter News Today

Merck KGaA, Darmstadt, Germany, Announces Leadership Change for North America and Global Innovative Medicine Franchises in Healthcare News provided by Share this article Share this article DARMSTADT, Germany, Feb. 4, 2021 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, which operates its Healthcare business sector as EMD Serono in the US and Canada, today announced that Rehan Verjee has made the decision to leave his position as President of EMD Serono and Global Head of Innovative Medicine Fr...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic ... Athenex, Inc.December 15, 2020 GMT Klisyri is the first FDA approved proprietary product for Athenex First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course Klisyri will be manufactured by Athenex Almirall will launc...

is the first FDA approved proprietary product for Athenex First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course Klisyri will be manufactured by Athenex Almirall will launch Klisyri in the U.S. in first quarter 2021 BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of no...

Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis -- Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) on the face or scalp -- Actinic keratosis is the second most common diagnosis made by dermatologists in the United States1 -- In one of the largest Phase III clinical study programs2 ever conducted for a topical AK treatment, tirbanibulin demonstrated compl...